1
|
Ogata R, Takemoto S, Fukuda M, Senju H, Nakatomi K, Sugasaki N, Tomono H, Suyama T, Shimada M, Akagi K, Hayashi F, Dotsu Y, Taniguchi H, Gyotoku H, Yamaguchi H, Nagashima S, Soda H, Kinoshita A, Mukae H. 316P Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Takemoto S, Fukuda M, Senju H, Nakatomi K, Sugasaki N, Ogata R, Tomono H, Suyama T, Shimada M, Akagi K, Hayashi F, Gyotoku H, Yamaguchi H, Nagashima S, Soda H, Kinoshita A, Mukae H. EP08.04-005 Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Hayashi F, Taniguchi H, Takayuki S, Umeyama Y, Dotsu Y, Gyotoku H, Senju H, Takemoto S, Yamaguchi H, Ono S, Tomono H, Shimada M, Soda H, Fukuda M, Hiroshi M. A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Ono S, Senju H, Taniguchi H, Tomono H, Shimada M, Hayashi F, Suyama T, Honda N, Umeyama Y, Dotsu Y, Gyotoku H, Takemoto S, Yamaguchi H, Fukuda M, Soda H, Mukae H. A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Tsujino S, Ikeda T, Taniguchi H, Shimada M, Gyoutoku H, Senju H, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H. P2.07-045 A Retrospective Analysis of Nivolumab-Related Pneumonitis in Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Fukuda M, Okumura M, Arimori K, Takahira A, Mori M, Nakamura D, Shimada M, Taniguchi H, Gyotoku H, Senju H, Ikeda T, Yamaguchi H, Nakatomi K, Tsuchiya T, Mukae H, Ashizawa K. P1.03-015 The Relationship between the UGT1A1*27 and UGT1A1*7 Genetic Polymorphisms and Irinotecan-Related Toxicities in Patients with Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Goto T, Kim YI, Funakoshi K, Teraminami A, Uemura T, Hirai S, Lee JY, Makishima M, Nakata R, Inoue H, Senju H, Matsunaga M, Horio F, Takahashi N, Kawada T. Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways. Am J Physiol Endocrinol Metab 2011; 301:E1022-32. [PMID: 21862726 DOI: 10.1152/ajpendo.00061.2011] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Peroxisome proliferator-activated receptors (PPARs) control energy homeostasis. In this study, we showed that farnesol, a naturally occurring ligand of PPARs, could ameliorate metabolic diseases. Obese KK-Ay mice fed a high-fat diet (HFD) containing 0.5% farnesol showed significantly decreased serum glucose level, glucosuria incidence, and hepatic triglyceride contents. Farnesol-containing HFD upregulated the mRNA expressions of PPARα target genes involved in fatty acid oxidation in the liver. On the other hand, farnesol was not effective in upregulating the mRNA expressions of PPARγ target genes in white adipose tissues. Experiments using PPARα-deficient [(-/-)] mice revealed that the upregulation of fatty acid oxidation-related genes required PPARα function, but the suppression of hepatic triglyceride accumulation was partially PPARα-dependent. In hepatocytes isolated from the wild-type and PPARα (-/-) mice, farnesol suppressed triglyceride synthesis. In luciferase assay, farnesol activated both PPARα and the farnesoid X receptor (FXR) at similar concentrations. Moreover, farnesol increased the mRNA expression level of a small heterodimer partner known as one of the FXR target genes and decreased those of sterol regulatory element-binding protein-1c and fatty acid synthase in both the wild-type and PPARα (-/-) hepatocytes. These findings suggest that farnesol could improve metabolic abnormalities in mice via both PPARα-dependent and -independent pathways and that the activation of FXR by farnesol might contribute partially to the PPARα-independent hepatic triglyceride content-lowering effect. To our knowledge, this is the first study on the effect of the dual activators of PPARα and FXR on obesity-induced metabolic disorders.
Collapse
Affiliation(s)
- Tsuyoshi Goto
- Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Mizuno N, Senju H, Sekiguchi K, Yoshida K, Kasai K, Sato H. A standard of AmpliType PM typing from aged evidentiary samples. J Forensic Sci 2001; 46:677-80. [PMID: 11373006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
In analyzing aged samples by the AmpliType PM PCR amplification and Typing kit, it was occasionally observed that color developed typing strips had dark allele dots on PM loci but no visible S dot. Since the S dot acts as a minimum dot intensity control to determine positive alleles on the PM loci, it is necessary to apply another control system. To achieve positive PM typing from a degraded DNA sample that is inferred to be derived from a single donor, a standard has been adopted wherein loci from which sufficient PCR products are observed on agarose gel can be typed. The objective determination of sufficient PCR was done by comparison between band peak height of each locus generated from a sample and that of the corresponding locus generated from two nanograms (recommended minimum quantity as template DNA) of the control DNA provided in the kit.
Collapse
Affiliation(s)
- N Mizuno
- Division First Forensic Science, National Research Institute of Police Science, Kashiwa, Chiba, Japan.
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
A multiplex typing method of the tetrameric short tandem repeat (STR) loci TH11, D9S304, and D3S1744 was developed. The allelic ladder included alleles 6-11 (80-100bp) and 9.3 (95bp) for TH01, alleles 6-15 (125-161 bp) for D9S304, and alleles 13-22 (174-210bp) for D3S1744. The observed heterozygosity of D9S304 was 0.851. The combined discrimination power of the three loci was 0.991.
Collapse
Affiliation(s)
- K Fujii
- Third Medico-Legal Section, National Research Institute of Police Science, Chiba, Japan.
| | | | | | | | | | | | | |
Collapse
|
10
|
Tsunawake N, Tahara Y, Yukawa K, Senju H. [Body composition, VO2 max and O2 debt max in elite senior high school male cyclists]. Ann Physiol Anthropol 1993; 12:351-62. [PMID: 8123185 DOI: 10.2114/ahs1983.12.351] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
This study was performed to evaluate the physical resources for elite male cyclists of senior high school. Nine track cyclists (mean age, 17.4 years) and seven road cyclists (mean age, 17.3 years) were examined for body composition and cardiorespiratory function (VO2 max and O2 debt max), from 1988 to 1992. These measurements were compared with those of elite junior cyclists, and the progress of physiological function due to one-year training was examined for 7 cyclists. The results were as follows: 1. The mean parameters for track cyclists were recorded: percentage body fat (%Fat): 10.3%; lean body mass (LBM): 56.5kg; VO2 max: 3.93l/min, 62.5ml/kg.min; O2 debt max: 8.81l, 139.1ml/kg. 2. The mean parameters for road cyclists were recorded: %Fat: 10.9%; LBM: 54.9kg; VO2 max: 3.78l/min, 61.4ml/kg.min; O2 debt max: 7.89l, 128.4ml/kg. 3. The average %Fat, LBM, LBM/Ht, VO2 max and O2 debt max were not significantly different between track and road cyclists. 4. The average %Fat and VO2 max (ml/kg.min) of track and road cyclists were similar to those of elite junior cyclists. 5. By training for one year, the average VO2 max (ml/kg.min) and O2 debt max (ml/kg) showed a significant increase of approximately 13.6% and 22.6% respectively. These results indicated that through training 9 track and 7 road cyclists had achieved a superior body composition, aerobic work capacity and anaerobic work capacity, equal to those of elite junior cyclists.
Collapse
|